BR112017016428A2 - "pharmaceutically acceptable compound or salt, pharmaceutical composition, use of a pharmaceutically acceptable compound or salt, and method for treating a malignant hyperproliferative disorder, an obesity associated metabolic condition, an autoimmune disorder or an inflammatory disorder"; - Google Patents

"pharmaceutically acceptable compound or salt, pharmaceutical composition, use of a pharmaceutically acceptable compound or salt, and method for treating a malignant hyperproliferative disorder, an obesity associated metabolic condition, an autoimmune disorder or an inflammatory disorder";

Info

Publication number
BR112017016428A2
BR112017016428A2 BR112017016428A BR112017016428A BR112017016428A2 BR 112017016428 A2 BR112017016428 A2 BR 112017016428A2 BR 112017016428 A BR112017016428 A BR 112017016428A BR 112017016428 A BR112017016428 A BR 112017016428A BR 112017016428 A2 BR112017016428 A2 BR 112017016428A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
salt
disorder
acceptable compound
treating
Prior art date
Application number
BR112017016428A
Other languages
Portuguese (pt)
Other versions
BR112017016428B1 (en
Inventor
Olsson Elisabeth
MELLSTEDT Håkan
Vågberg Jan
Byström Styrbjörn
Original Assignee
Kancera Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kancera Ab filed Critical Kancera Ab
Publication of BR112017016428A2 publication Critical patent/BR112017016428A2/en
Publication of BR112017016428B1 publication Critical patent/BR112017016428B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

um composto de fórmula (i´) ou (i´´) ou um sal farmaceuticamente aceitável do mesmo. o composto é um inibidor de atividade de enzimas cinase de mamífero, incluindo atividade de tirosina quinase ror1 e pode ser usado no tratamento de distúrbios associados a tal atividade.a compound of formula (i´) or (i´´) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian enzyme kinase activity, including ror1 tyrosine kinase activity, and may be used in the treatment of disorders associated with such activity.

BR112017016428-0A 2015-02-02 2016-02-01 PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT, PHARMACEUTICAL COMPOSITION, AND, USE OF A PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT BR112017016428B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15153394 2015-02-02
EP15153394.0 2015-02-02
PCT/EP2016/052091 WO2016124553A1 (en) 2015-02-02 2016-02-01 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity

Publications (2)

Publication Number Publication Date
BR112017016428A2 true BR112017016428A2 (en) 2018-04-10
BR112017016428B1 BR112017016428B1 (en) 2023-10-24

Family

ID=52449976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016428-0A BR112017016428B1 (en) 2015-02-02 2016-02-01 PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT, PHARMACEUTICAL COMPOSITION, AND, USE OF A PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT

Country Status (14)

Country Link
US (1) US10550113B2 (en)
EP (1) EP3253754B1 (en)
JP (1) JP6629884B2 (en)
KR (1) KR102493943B1 (en)
CN (1) CN107567445B (en)
AU (1) AU2016214492B2 (en)
BR (1) BR112017016428B1 (en)
CA (1) CA2973773C (en)
ES (1) ES2875737T3 (en)
HK (1) HK1247923A1 (en)
IL (1) IL253380B (en)
MX (1) MX2017009600A (en)
WO (1) WO2016124553A1 (en)
ZA (1) ZA201705933B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
WO2018011138A1 (en) * 2016-07-11 2018-01-18 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
JP7378267B2 (en) 2018-11-12 2023-11-13 東ソー株式会社 Cobalt complex, method for producing the same, and method for producing a cobalt-containing thin film
CN112574176B (en) * 2019-09-27 2024-03-15 隆泰申医药科技(南京)有限公司 Heteroaryl compound and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045929A1 (en) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
SE0202462D0 (en) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
SE0202464D0 (en) 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
CN101830899A (en) 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents
EP1833829A2 (en) 2004-12-23 2007-09-19 F. Hoffmann-Roche AG Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
PL1861387T3 (en) 2005-01-28 2014-08-29 Dae Woong Pharma Benzimidazole derivatives and pharmaceutical compositions thereof
EP1891069A1 (en) 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
JP2007063225A (en) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
WO2007072017A2 (en) 2005-12-22 2007-06-28 The Institute Of Cancer Research Enzyme inhibitors
JP2009523845A (en) 2006-01-23 2009-06-25 クリスタルゲノミクス インコーポレーテッド IMIDAZOPYRIDINE DERIVATIVE INHIBITING PROTEIN KINASE ACTIVITY, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US20100234593A1 (en) 2007-03-30 2010-09-16 Astrazeneca Ab Imidazo[4,5-B]Pyridine-7-Carboxamides 704
WO2008121064A1 (en) 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705
WO2009001021A1 (en) 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
US20110003809A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
WO2011066211A1 (en) 2009-11-24 2011-06-03 Glaxosmithkline Llc Azabenzimidazoles as fatty acid synthase inhibitors
WO2011079902A2 (en) 2009-12-18 2011-07-07 Biolnvent International Ab Biological materials and uses thereof
ES2567552T3 (en) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] pyridine derivatives such as ALK and JAK modulators for the treatment of proliferative disorders

Also Published As

Publication number Publication date
KR102493943B1 (en) 2023-01-31
JP2018507255A (en) 2018-03-15
JP6629884B2 (en) 2020-01-15
IL253380A0 (en) 2017-09-28
KR20170113629A (en) 2017-10-12
US10550113B2 (en) 2020-02-04
HK1247923A1 (en) 2018-10-05
WO2016124553A1 (en) 2016-08-11
CA2973773C (en) 2023-10-17
EP3253754B1 (en) 2021-03-31
CN107567445A (en) 2018-01-09
EP3253754A1 (en) 2017-12-13
IL253380B (en) 2021-07-29
ES2875737T3 (en) 2021-11-11
US20180002329A1 (en) 2018-01-04
ZA201705933B (en) 2018-12-19
CN107567445B (en) 2021-06-29
AU2016214492A1 (en) 2017-08-24
BR112017016428B1 (en) 2023-10-24
MX2017009600A (en) 2017-11-22
AU2016214492B2 (en) 2020-05-07
CA2973773A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
BR112017016428A2 (en) "pharmaceutically acceptable compound or salt, pharmaceutical composition, use of a pharmaceutically acceptable compound or salt, and method for treating a malignant hyperproliferative disorder, an obesity associated metabolic condition, an autoimmune disorder or an inflammatory disorder";
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
CL2020002146A1 (en) N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as hpki inhibitors to treat cancer.
SA518392101B1 (en) Benzimidazole Derivatives as Modulators of ROR-GAMMA
SA518391624B1 (en) Modulators of ROR-GAMMA
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
BR112017003054A2 (en) aminopyrimidinyl compounds as jak inhibitors
TR201901312T4 (en) Tetrahydronaphthalene derivatives that inhibit the Mcl-1 protein.
BR112019002576A2 (en) compound, medicament¸ methods for inhibiting gcn2 in a mammal and for prophylaxis or treating cancer in a mammal, and use of the compound or a salt thereof
BR112016028288A2 (en) compound, pharmaceutical composition, methods for treating an individual with a disease or condition and for inhibiting kinase, and use of a compound.
BR112016028818A2 (en) pharmaceutical composition, methods of treating a disease or condition, inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide and inhibiting excessive or destructive immune reactions or cancer cell growth or proliferation, kit, compound, salt, isomer, or a pharmaceutically acceptable mixture thereof, and, use of a compound, a salt, isomer, or a pharmaceutically acceptable mixture thereof.
BR112016028819A2 (en) pharmaceutical composition, methods for treating a disease or condition in a human and for inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide and excessive or destructive immune reactions or cancer cell growth or proliferation, kit, compound, pharmaceutically acceptable salt , isomer or mixture thereof, and use of a compound, pharmaceutically acceptable salt or mixture thereof.
BR112018005163A2 (en) cenicriviroc combination therapy for fibrosis treatment
UA109878C2 (en) Isoquinolinone derivatives, pharmaceutical composition based on them (variants), and method of treating diseases (variants)
EA201790660A1 (en) KINAZ INHIBITOR
BR112016028642A2 (en) compound, pharmaceutical composition, method of treating a disease or condition, method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide, method of inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, and, use of a compound, salt, isomer or a pharmaceutically acceptable mixture thereof.
PH12016502353A1 (en) Pharmaceutical composition
BR112018069515A2 (en) use of masitinib to treat a subpopulation of patients with amyotrophic lateral sclerosis
TW201613577A (en) Pharmaceutical combinations
BR112015026247A2 (en) methods for cancer treatment using tor kinase inhibitor combination therapy
BR112018007947A2 (en) use of ep4 receptor antagonists for the treatment of liver cancer associated with nash
PL410665A1 (en) Arginase inhibitors and their therapeutical applications
BR112018069930A2 (en) powder agonists, compounds, pharmaceutical compositions, and methods of using them
EA201691600A1 (en) DIHYDROPYRIDINOUS INHIBITORS MGAT2 FOR USE IN THE TREATMENT OF METABOLIC DISORDERS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2016, OBSERVADAS AS CONDICOES LEGAIS